CSRT.L Regulatory News (CSRT)

Registered Number 406711

Consort Medical plc (the "Company")

Total Voting Rights

The Company hereby notifies the market of the following disclosure with respect to the share capital and voting rights of the Company: 

As at the 31 March 2015, the capital of the Company consists of 49,074,982 ordinary shares of 10 pence each with voting rights.

Therefore, the total number of voting rights in the Company is 49,074,982.

Enquiries:

Consort Medical plc

Iain Ward, Company Secretary 01442 867920

Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

The Group has facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, UK; in Monheim and Zwickau, Germany; and in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.